A simple meta-analysis of the eight surveys of microRNA (miRNA) 
Introduction
MicroRNAs (miRNAs) are 22nt long non-coding RNAs that, since their initial discovery nearly two decades ago, have been found to be ubiquitously involved in cellular processes throughout the plant and animal kingdoms 1 . MiRNAs act to regulate gene expression at both the transcriptional and posttranscriptional level thereby influencing hundreds of normal cell functions 1 . Further, dysregulation of miRNAs has been shown to play a role in dozens of human diseases, including cancers 2 .
We recently reported on an extensive survey of dysregulation of miRNA expression in endometrial endometrioid adenocarcinomas and endometrial serous adenocarcinomas 3 and have followed that with a just completed survey of miRNA dysregulation in uterine carcinosarcomas 4 . Our two surveys bring to eight the total number of extant studies of miRNA dysregulation in endometrial cancers [3] [4] [5] [6] [7] [8] [9] [10] . These surveys were carried out on a wide range of sample sizes, utilized different methodologies, and included a spectrum of endometrial cancer types, yet the compilation of results presented here reveals a core set of sixteen miRNAs whose expression was found to be significantly dysregulated in three or more of the studies. Examination of these miRNAs reveals that they affect central cellular processes and are, as a group, all members of evolutionarily old miRNA families. Thus, these commonly dysregulated miRNAs represent the first true candidates forming a core panel that, with further study, comprise a miRNA signature of endometrial cancer and, perhaps, other cancers as well. To date, there have been eight surveys of miRNA expression in endometrial cancers of which seven have been published and the eighth is in preparation [3] [4] [5] [6] [7] [8] [9] [10] .
The general characteristics of these miRNA surveys are presented in Table 1 . As noted, the sample sizes and representation of both benign endometrium controls and the endometrial tumors types vary widely from study to study. Further, these studies surveyed a varied and only partially overlapping minority of the so far known total of 1,424 human miRNAs (miRBase Release 17, April 2011). Whatever the variation in sample size, tumor composition, and miRNA coverage may be, however, the techniques for determining miRNA expression levels are limited. In fact, there are but two methods available.
One, the hybridization array, involves fluorescently labeling DNA fragments generated by reverse-transcription (RT) and hybridizing them to grids spotted with synthetic oligonucleotides composed of reverse complement (antisense) miRNA sequences. The fluorescence intensity of each position in the array is then measured and analyzed relative to known standards. The alternative technology, also based upon reverse transcription of cellular RNA, involves quantitative PCR (qPCR) of RT-generated cDNA fragments using primers and fluorescently labeled probes (TaqMan assays) specific to individual miRNAs. These assays are also normalized to endogenous RNA standards for subsequent expression analyses.
Taken together, the eight miRNA surveys overlap by, perhaps, only a few dozen miRNAs and yet a panel of sixteen miRNAs are found to be significantly dysregulated in endometrial cancers relative to benign endometrium in at least three of the eight surveys (Table 2) . Moreover, half of these sixteen are found to be significantly dysregulated in endometrial cancers relative to benign endometrium in at least four of the eight surveys and two, miR-210 and miR-205, are found in six of eight and seven of eight surveys respectively.
Discussion
MiRNAs function to both preserve the overall homeostatic regulation of cellular processes and participate in normal cellular state transitions. Several miRNAs can target the same mRNA message and each miRNA can have multiple targets. This establishes networks of gene regulation involving both feed-back and feed-forward loops. Thus, when dysregulated, miRNAs can potentially be extremely disruptive. In cancers, miRNAs have been seen to be both significantly over-expressed and significantly under-expressed relative to benign tissues and to function as tumor suppressors or oncogenes depending upon the tumor type and tissue of origin 11, 12 . However, it is reasonable to expect that any particular miRNA will function consistently within the same cancer type. The sixteen miRNAs presented here are not only consistently either over-or under-expressed but can be expected to be carrying out the same pathogenic role in endometrial cancers regardless of histologic type. Proof of this principle is the presence of the entire miR-200 family of miRNAs in Table 2 . This family, which emerged in eumetazoan genomes more than 500 million years ago 13 , is composed of five miRNAs in two polycistrons, years ago with the emergence of the bilateria. In fact, all of the miRNAs found in Table 2 are members of ancient miRNA lineages with most appearing well before the emergence of the Chordates 5 x 10 8 years ago (Table 3) . This is not surprising, since cancer is a dramatic re-programming of basic cellular functions 11 it stands to reason that deeply rooted, highly conserved miRNAs involved in regulating basic cellular functions would be preferentially affected. Table 3 . Evolutionary emergence of the miRNAs in Table 2 . Taxon assignments are based upon detection of individual miRNAs in representative species reported in Sempere et al. 13 .
Eumetazoa 700,000,000 miR-10 21 .
The miRNA dysregulation signature of human endometrial cancer presented here, because it is deeply rooted in animal evolution, is likely part of a generic dysregulation signature in many human cancers. Most of these miRNAs are seen to be significantly dysregulated in other cancers as well including leukemia, ovary, lung, prostate, colorectal, brain, and pancreas 22 . It is certainly possible that these observations are statistical artifact since miRNAs with low miRBase archive numbers 23 are those that were first identified and have been included in various arrays for several years. On the other hand, these miRNAs continue to be represented even as the size and complexity of miRNA arrays has increased.
If there is a functional overrepresentation of the more ancient miRNAs in human cancers, adding to and overlaying this background are many miRNAs that appeared following the emergence of the land animals 13 . The human miRNAome retains the ancient miRNAs but also has hundreds of new miRNAs that are only found in mammals and more only found in primates or in hominids 13 . When seeking to derive a true miRNA signature of human endometrial cancers it is reasonable to expect that endometrialspecific miRNA expression patterns will be layered over the ancient, generic "cancer pattern" presented here. The task now is to identify these histologyspecific miRNAs, add them to the core miRNAs, and use them to develop diagnostic and prognostic assays as well as identify their mRNA and pathway targets. 
